Neurovalens
PrivateLast Round
Early Funding
Aug 19, 2025
Total Funding Raised
$25.37M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Neurovalens is a health-technology company that develops non-invasive neurostimulation products to address global health issues.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, D2C Brands, Health IoT, Clinical Trials
Business Model
B2C
Customer Profile
Hardware Sales, Subscription SaaS
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurovalens Comparables
Compare Neurovalens with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Znicz | 85% | |
| Parasym | 79% | |
| Earable Neuroscience | 79% |
Neurovalens Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Aug 19, 2025 | ||||
| VC Round | Aug 19, 2025 | ||||
| Series A Extension | Apr 8, 2024 | ||||
| Debt | Jan 21, 2022 | ||||
| Grant | Sep 1, 2021 | ||||
VC Round | Jul 20, 2020 |
Key People
Founding team and executive leadership
Neurovalens Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ACF Investors | VC Round, Early Funding |
| MedTech Innovator | Series A Extension |
| Future Fund | VC Round |
| Whiterock Finance | Debt, VC Round, Early Funding |
| British Business Bank | Series A Extension, Series A, Early Funding |
| Invest Northern Ireland | Series A Extension, Grant |
| IQ Capital | VC Round, Series A Extension, Series A, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 128% MoM.
- Jul 16, 2026
Grew 15% QoQ, from 26 to 30 employees.
Neurovalens Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Neurovalens's valuation, stock price, and market status.
Is Neurovalens a public or private company?
Neurovalens is a private company.
What is the current stock price of Neurovalens?
Neurovalens is a private company with no public stock price. No recent secondary market data is available.
How much is Neurovalens worth (valuation)?
Valuation information for Neurovalens is not publicly available.
Can I buy Neurovalens stock?
Neurovalens shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Neurovalens's last funding round?
Neurovalens's most recent funding round was Debt on August 19, 2025.
Who are the main investors in Neurovalens?
Key investors in Neurovalens include IQ Capital.
Will Neurovalens IPO soon?
No public IPO plans have been announced for Neurovalens.
How can I track Neurovalens secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neurovalens's secondary market activity and sign up for updates.